Cargando…
Targeting tumor vulnerabilities associated with loss of heterozygosity
We show that N-acetyltransferase 2 (NAT2) loss of heterozygosity can be targeted in >4% of colorectal cancers with the use of a small molecule. We identify and describe the effect of a compound that impairs the growth of colorectal tumors with slow NAT2 activity by half when compared to wild-type...
Autores principales: | Rendo, Veronica, Stoimenov, Ivaylo, Sjöblom, Tobias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469497/ https://www.ncbi.nlm.nih.gov/pubmed/32944621 http://dx.doi.org/10.1080/23723556.2020.1759390 |
Ejemplares similares
-
Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy
por: Rendo, Veronica, et al.
Publicado: (2020) -
Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer
por: Rendo, Veronica, et al.
Publicado: (2020) -
Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy
por: Zhang, Xiaonan, et al.
Publicado: (2021) -
Tumor-targeting vaccination instructs graft-vs.-tumor immune responses
por: Manzo, Teresa, et al.
Publicado: (2013) -
Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages
por: Cavnar, Michael J, et al.
Publicado: (2014)